Table of Contents - WOC 2012

FP-RET-SA 197 (8)
RaScaL Study: A Novel Treatment Strategy for Diabetic Macular
Edema Associates with Peripheral Retinal Nonperfusion on
Ultrawide-field Angiography
Suner Ivan (1,2) , Hammer Mark (1,2) , Grizzard Sanderson (1,2)
1. Retina Associates of Florida, P.A.
2. University of South Florida
Objective: The RaScaL study was designed to evaluate the efficacy, durability,
and safety of a combination strategy of a single intervention of ranibizumab
+ peripheral scatter laser in a subgroup of patients with diabetic macular
edema associated with peripheral nonperfusion on ultrawide-field angiography
(UWFA).
Methods: Patients with diabetic macular edema and peripheral retinal
nonperfusion on UWFA were randomized to single intervention of either
RaScaL treatment (ranibizumab 0.5 mg + UWFA-directed peripheral scatter
laser) or standard treatment (triamcinolone acetate 4 mg + macular laser)
at baseline. Monthly evaluations were performed to evaluate for response.
Recurrence was determined by loss of 5 letters on ETDRS vision chart or
increase of 50 microns on optical coherence tomography.
Results: There was a nonstatistically-significant trend to better vision (13 vs 10
letters, p=0.84) and resolution of fluid on OCT (214 vs 106 microns, p=0.08) in
the RaScaL group. However, there was an impressive statistically-significant
difference (33% vs 80%, p